Maxwell Skor
Stock Analyst at Morgan Stanley
(2.90)
# 1,709
Out of 5,072 analysts
7
Total ratings
66.67%
Success rate
39.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Initiates: Overweight | $190 | $219.88 | -13.59% | 1 | Oct 16, 2025 | |
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $207.77 | -30.69% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $212.33 | +17.74% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $4.30 | +179.07% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.11 | +800.90% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $2.43 | +46.09% | 2 | Nov 20, 2024 |
Cidara Therapeutics
Oct 16, 2025
Initiates: Overweight
Price Target: $190
Current: $219.88
Upside: -13.59%
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $207.77
Upside: -30.69%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $212.33
Upside: +17.74%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $4.30
Upside: +179.07%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.11
Upside: +800.90%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $2.43
Upside: +46.09%